Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
February 11, 2025
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
February 2, 2022
Related Post
-
-
Oncocyte Prices $29.1 Million Equity Offering
February 10, 2025
-
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
February 7, 2025
-
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
February 5, 2025